Novo Nordisk confirms it will cut US list prices for Wegovy, Ozempic and Rybelsus in 2027

Novo Nordisk has confirmed it will cut the US list price of its semaglutide medicines starting January 1, 2027. The new wholesale acquisition cost will be $675 per month for all doses of Wegovy, Ozempic and Rybelsus, the company said ^[1].

That works out to roughly a 50% reduction from the current list price of Wegovy and about a 35% reduction for Ozempic ^[1]. The company's second-quarter 2026 financial report described the same change — $675 for Wegovy injection and tablets and for Ozempic, with cuts of about 50% and 35% — and noted it expects the move to affect 2027 cash flow ^[2]. The press announcement covering all three brands is the more detailed of the two sources on Rybelsus ^[1].

"The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or coinsurance benefit designs," said Jamey Millar, executive vice president of US operations at Novo Nordisk ^[1].

Novo Nordisk said the cut does not change its existing direct-to-patient self-pay programs, which include savings offers, telehealth partnerships and NovoCare Pharmacy ^[1]. The Wegovy pill, launched earlier in 2026, has been sold through more than 70,000 pharmacies and nine telehealth partners at $149 to $299 per month depending on dose ^[2].

What list price actually means

List price is the sticker figure drugmakers set before rebates and discounts are negotiated with insurers and pharmacy benefit managers. Most insured patients never pay it directly. But it still sets the number used to calculate coinsurance percentages, counts toward deductibles before coverage kicks in, and anchors cash-pay benchmarks. Novo Nordisk framed the change as helping exactly those groups — people with high-deductible plans, coinsurance tied to list price, or coverage gaps ^[1].

The company's own numbers show why the change matters to its finances. In the second quarter of 2026, US Wegovy injectable sales fell 22% at constant currency even as weekly US injectable prescriptions rose to roughly 310,000 from about 280,000 a year earlier ^[2]. Self-pay accounted for about 35% of US injectable Wegovy volume, up from 10% to 15% a year earlier, at a materially lower price point ^[2]. Total US obesity care revenue grew 4% while the US branded obesity market grew 87% by volume ^[2].

The source materials tie the 2027 cut to the broader US policy picture, including the Most Favoured Nations agreement and Medicaid coverage reductions in several states, which the earnings review characterized as "a volume-for-price trade with the price side arriving first" ^[2]. The specific terms of the Medicare negotiated price taking effect the same day are not spelled out in these sources.

Why it matters for patients

If your plan charges a percentage of the drug's price rather than a flat copay, a lower list price generally means a smaller percentage. If you are working through a deductible, a lower list price means the amount charged against that deductible each month is smaller — though it also means the deductible takes longer to satisfy. For people with flat copays and full coverage, the change may not show up at the pharmacy counter at all.

Cash-pay patients are in a more complicated spot. Novo Nordisk says the self-pay programs are unaffected by the list price change ^[1], and current self-pay pricing for the oral product sits well below $675 ^[2]. What the January 2027 list price does to those separate programs is not stated.

What happens next

• October 1, 2026: CVS Caremark is set to add other weight-loss medications to its largest commercial template formularies, ending the exclusive position Novo Nordisk secured in July 2025 at a pharmacy benefit manager with roughly 26% of the US market ^[2].
• End of 2026: A US regulatory decision on CagriSema for obesity is due ^[2].
• January 1, 2027: The $675 list price takes effect ^[1].

The Medicare Part D "Bridge" pilot went live July 1, 2026, covering a majority of beneficiaries at a $50 copay; Novo Nordisk called early volumes encouraging but said it was too early to judge ^[2].